Eravacycline: from clinical trials to its potential place in everyday therapy
While clinical data remain limited, eravacycline appears promising for the treatment of infections caused by MDR pathogens, particularly in patients with limited therapeutic options or intolerance to β-lactams. As resistance mechanisms continue to evolve, the role of eravacycline in real-world clinical practice may extend beyond its current indications, warranting further research to define its optimal therapeutic applications.
Authors
- Nadia Castaldo (ORCID: https://orcid.org/0000-0003-4660-0450)
- Antonio Roig Vena
- L Taramasso
- Daniele Roberto Giacobbe
- Alberto Fantin
- Matteo Bassetti
Institutions
- University of Udine (IT)
- Ospedale Policlinico San Martino (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Current Opinion in Infectious Diseases
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1097/qco.0000000000001157
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00